Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 16/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 16/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.41 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12437175 | 0.82 | MEN1 (0.63) | MEN1KMT2ANPC1ATM | |
| SCHEMBL22299557 | 0.73 | KMT2A (0.49) | MEN1KMT2ANPC1ATM | |
| SCHEMBL3159420 | 0.70 | OPRL1 (0.49) | MEN1KMT2ATP53MAPT | |
| SCHEMBL9658352 | 0.68 | SLC2A1 (0.57) | MEN1KMT2ANPC1TP53MAPT | |
| SCHEMBL9658918 | 0.68 | SLC2A1 (0.57) | MEN1KMT2ANPC1TP53MAPT | |
| SCHEMBL20711471 | 0.68 | MEN1 (0.50) | MEN1KMT2ANPC1ATM | |
| SCHEMBL3045360 | 0.68 | ALDH1A1 (0.47) | MEN1KMT2ATP53MAPTKDM4E | |
| SCHEMBL11923150 | 0.67 | KMT2A (0.52) | MEN1KMT2ANPC1ATM | |
| SCHEMBL18650042 | 0.66 | TP53 (0.44) | MEN1KMT2ATP53MAPTKDM4E | |
| SCHEMBL9094196 | 0.66 | SLC2A1 (0.67) | MEN1KMT2ANPC1TP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8435978-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2013-05-07 | — | — | US | disclosed |
| US-20100324009-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2010-12-23 | — | — | US | disclosed |
| US-20100324009-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2010-12-23 | — | — | US | disclosed |
| US-20100317644-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2010-12-16 | — | — | US | disclosed |
| US-20080153843-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | GRUENENTHAL GMBH (DE) | 2008-06-26 | — | — | US | disclosed |
| US-20080153843-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | GRUENENTHAL GMBH (DE) | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317644-A1 | Substituted Sulfonamide Compounds | SULT2A1, STS, SULT1A1 | MEN1 4354/4885KMT2A 1686/4885NPC1 2707/4885 |
| US-20100324009-A1 | Substituted Sulfonamide Compounds | SULT2A1, STS, SULT1A1 | MEN1 4354/4885KMT2A 1686/4885NPC1 2707/4885 |
| US-20080153843-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | SULT2A1, STS, SULT1A1 | MEN1 4354/4885KMT2A 1686/4885NPC1 2707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.